Details of the Drug Combination

General Information of Drug Combination (ID: DCP5KKG)

Drug Combination Name
Eflornithine Brincidofovir
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Eflornithine   DMJOQM3 Brincidofovir   DMS0PND
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 3.76
Bliss Independence Score: 3.76
Loewe Additivity Score: 4.65
LHighest Single Agent (HSA) Score: 4.72

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Eflornithine
Disease Entry ICD 11 Status REF
African trypanosomiasis 1F51 Approved [2]
Trypanosomiasis 1D51-1F53 Phase 2 [3]
Colon cancer 2B90.Z Investigative [4]
Familial adenomatous polyposis 2B90.Y Investigative [4]
Eflornithine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Ornithine decarboxylase (ODC1) TTUMGNO DCOR_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
Indication(s) of Brincidofovir
Disease Entry ICD 11 Status REF
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [5]

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5176).
3 ClinicalTrials.gov (NCT01636128) Urinary Biomarker Study With Sulindac and Difluoromethylornithine. U.S. National Institutes of Health.
4 Eflornithine FDA Label
5 A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. Br J Pharmacol. 2020 May 1;10.1111/bph.15094.
6 Plasmodium falciparum and Plasmodium berghei: effects of ornithine decarboxylase inhibitors on erythrocytic schizogony. Exp Parasitol. 1987 Oct;64(2):237-43.